“Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma”, Hematol Meeting Rep, vol. 3, no. 1, Jun. 2009, doi: 10.4081/hmr.v3i1.525.